Regeneron buys Art Krieg’s biotech startup for a discount price, boosting I/O pipeline

John Carroll

Editor & Founder

Jumping into the M&A game, Regeneron has scooped up a beaten down Checkmate Pharmaceuticals for $250 million in cash, bagging its lead drug for melanoma …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron buys Art Krieg’s biotech startup for a discount price, boosting I/O pipeline

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Where the money is: The top 100 venture investors in biotech

Lilly pays $10M upfront for Organovo’s FXR agonist program

Repare to lay off 75% of staff; Castle Creek inks $75M royalty deal

Alnylam eyes bigger diseases in more tissue types at ‘inflection point’ for siRNA

BridGene nets another Takeda deal amid plans to raise more funding and go public

How AI can address ongoing challenges in the life sciences industry

Re­gen­eron buys Art Krieg’s biotech start­up for a dis­count price, boost­ing I/O pipeline

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Regeneron buys Art Krieg’s biotech startup for a discount price, boosting I/O pipeline